Match Document Document Title
6596850 Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same  
The invention provides a LM609 grafted antibody comprising one or more CDRs having at least one amino acid substitution, where the LM609 grafted antibody has α v β 3 binding activity. Nucleic...
6596277 Methods of decreasing cell adhesion  
The present invention provides substantially pure integrins containing a novel β subunit designated as β 6 . The novel β 6 subunit forms heterodimers with α V and α F . Methods of...
6596848 Antibodies to NIMA interacting proteins  
A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA...
6592868 Methods for treating autoimmune diseases with 5C8-specific antibodies  
This invention provides methods of treating autoimmune diseases, including those selected from the group consisting of rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves'...
6590079 Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same  
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to α v β 3 . The Vitaxin antibody consists of at least one Vitaxin heavy chain...
6576236 Methods for stimulating T cell responses by manipulating a common cytokine receptor &ggr chain  
When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy....
6572856 Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies  
The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also...
6569431 Recombinant antibody fragments as autoantibody antagonists  
The invention provides methods and compositions for inhibiting autoantibody binding in demyelinating disease such as multiple sclerosis. The compositions comprise immunoglobulin CDR3 sequences...
6562949 Antibodies to viral encoded semaphorin protein receptor polypeptides  
The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for...
6558961 Immunodiagnostics using particle delivery methods  
Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the...
6555111 Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies  
Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF...
6551599 Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens  
The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of Campylobacter jejuni (Cj) only and (2) epitopes conserved...
6548061 Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration  
Novel compositions are described comprising the combined administration of serum complement proteins with complement-fixing antibodies. The antibodies specifically bind to one or more epitopes of...
6545128 Anti-bax inhibitor protein antibodies  
The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid...
6534058 Anti-C5 monoclonal antibodies  
The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in...
6534057 Method increasing the delayed-type hypersensitivity response by infusing LFA-1-specific antibodies  
Methods for treating and inhibiting disease and symptoms associated with the human immunodeficiency virus (HIV) are provided. The method includes transforming the human immunodeficiency virus (HIV)...
6528061 Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions  
A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a...
6528055 Methods of administering antibodies that specifically bind ACT-4-L-h-1 ligand  
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4 + T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified...
6528625 Anti-CCR5 antibodies and kits comprising same  
The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The...
6528493 Screening methods for identifying modulators of proliferation and differentiation of bone cells  
The present application relates to a compositions comprising a compound which modulates the activity of T1-M protein, the use of compounds which modulate the activity of T1-M protein, and an in...
6528269 Immunological agents specific for prion protein (PRP)  
The present invention is directed to a panel of monoclonal antibodies (Mabs) specific for murine prion protein PrP c . These Mabs can be applied to immunoblotting, cell surface immunofluorescent...
RE38008 Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof  
Methods for improved targeting of antibody, antibody fragments, peptides hormones, steroid hormones and conjugates thereof are disclosed. Enhanced delivery to target cells of antibodies or...
6517845 Mycobacterium tuberculosis superoxide dismutase  
The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis , methods of testing for an inhibitor of an M....
6514497 Inhibition of LERK-2-mediated cell adhesion  
Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate...
6511665 Antibodies to interleukin-1 receptors  
The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for...
6511664 Intercellular adhesion molecule—2 and its binding ligands  
The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as...
6509319 EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections  
A pharmaceutical composition comprising at least one antifungal agent and at least one chelator, and a method for administering the pharmaceutical composition to a patient having a fungal...
6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies  
The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune...
6506382 Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand  
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3...
6504013 Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody  
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise...
6503509 Method for receptor desensitization  
Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell...
6498237 Tumor necrosis factor antibodies  
The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is...
6497878 Treatment of cerebral disorders by inhibition of IL-8 binding to receptor  
Methods and compositions for treating or preventing cerebral stroke, cerebral infarction, cerebral edema, reperfusion injury and increased cerebral vascular permeability which employ an agent that...
6491914 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies  
An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an...
6485970 Immunointeractive antibody  
The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to...
6482408 Fibroblast growth factor 15 antibodies  
The present invention relates to antibodies directed to the human protein called Fibroblast Growth Factor 15.
6468531 Method of promoting cellular function  
The present invention relates, in general, to a method of producing a therapeutic effect and, in particular, to a method of using antibodies to promote cellular function, to antibodies suitable for...
6468547 Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies  
The present invention provides a method of enhancing the chemosensitivity and radiosensitivity of a neoplastic cell expressing an oncoprotein that stimulates proliferation of the cell, comprising...
6468529 Hepatocyte growth factor receptor antagonists and uses thereof  
Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to...
6468532 Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates  
Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody...
6458354 Molecular complexes which modify immune responses  
Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of...
6458355 Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates  
Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody...
6455042 Method of treating ulcerative colitis or crohn's disease by administering an antibody toαEβ7 integrin  
The present invention relates to a method for treating an autoimmune disease, such ulcerative coliteis or crohns disease characterized by lymphocyte accumulation at epithelial sites. The method...
6451311 Anti-procalcitonin antibodies and the preparation and use thereof  
The invention relates to anti-procalcitonin antibodies, their preparation and use, in particular in therapy and diagnostics. The antibodies comprise binding to procalcitonin but not to free...
6451310 Method for inhibiting an allergic response with a 5c8-specific antibody  
This invention provides a method of inhibiting an allergic response in a subject by inhibiting T cell activation of B cells, wherein said method comprises administering to the subject an antibody...
6451981 Antibodies against lymphocyte-associated cell surface protein LAM-1  
Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding...
6448021 Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies  
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding...
6447776 Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors  
The present invention describes monoclonal antibodies which are useful for the specific detection of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the...
6444206 Methods and compositions for inhibiting CD14 mediated cell activation  
This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The...
6440418 Methods of treating autoimmune diseases with gp39-specific antibodies  
The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune...